Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases

Journal of the Society for Gynecologic Investigation

Volumn 3, Issue 1, 1996, Pages 39-46

  Shaarawy, Mohamed ^a,b   Darwish, Nabil A ^a   Abdel Aziz, Omar ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b Roxy Building ^*  (Egypt)

Author keywords

gestational trophoblastic disease; Interleukin 2; soluble interleukin 2 receptor

Indexed keywords

BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

ADULT; ARTICLE; CANCER RISK; CHORIOCARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HIGH RISK PATIENT; HUMAN; HYDATIDIFORM MOLE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; TROPHOBLASTIC DISEASE;

ADOLESCENT; ADULT; CHORIOCARCINOMA; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CONFIDENCE INTERVALS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYDATIDIFORM MOLE; INTERLEUKIN-2; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RECEPTORS, INTERLEUKIN-2; REFERENCE VALUES; REGRESSION ANALYSIS; TROPHOBLASTIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 0030071545     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/1071-5576(95)00036-4     Document Type: Article

References (53)

1. Goldstein DP, Berkowitz RS. Gestational trophoblastic neoplasms: Clinical principles of diagnosis and management. Philadelphia, WB Saunders 1982:143-75.
2. Berkowitz RS, Hill JA, Kurtz CB, Anderson DJ. Effects of products of activated leucocytes, lymphokines and monokines on the growth of malignant trophoblastic cells in vitro. Am J Obstet Gynecol, 1988;158:199-206.
3. Balkrill FR, Burke F. The cytokine network. Immunol Today, 1989;10:299-304.
4. Ben-Rafael Z, Orieto R. Cytokines involvement in reproduction. Fertil Steril 1992;58:1093-9.
5. Wagnann TG. Maternal T cells promote placental growth and prevent spontaneous abortion. Immunol Lett 1988;17:297-302.
6. Anderson DJ, Hill JA, Haimovici F, Xu C. Application of new concepts in cell-mediated immunity to the development of effective antifertility vaccines. In: Runnebaum B, Raule T, Kiesel L, eds. Female contraception update and trends. Heidelberg, Germany: Springer-Verlag, 1982;351-5.
7. Nichols NS, Panayi G. Inhibition of interleukin production by retroplacental sera. Am J Reprod Immunol Microbiol 1985;9:6-11.
8. Berkowitz RS, Goldstein DP. Diagnosis and management of the primary hydatidiform mole. Obstet Gynecol 1988;15:252-62.
9. Oppeheim JJ, Ruscetti FW, Faltynek C. Cytokines. In: Stites DP, Terr AI, eds. Basic and clinical immunology. 7th ed. Norwalk, Connecticut: Appleton & Lange, 1991:78-100.
10. Mills GB, Hashimoto S, Hurteau JA, et al. Role of growth factors, their receptors, and oncogenes in the diagnosis, prognosis, follow-up and therapy of ovarian cancer. Diagn Oncol 1992;2: 39-54.
11. Waldmann TA. The interleukin 2 receptor. J Biol Chem 1991; 266:2681-4.
12. Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985;135:3172-7.
13. Rubin LA, Nelson D. The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med 1990; 113:619-45.
14. Dianarello CA, Mier JW. Lymphokines. N Engl J Med 1987; 317:940-45.
15. Oliver RTD. The clinical potential of interleukin-2. Br J Cancer 1988;58:405-09.
16. Leo R, Peest R, Hein R, et al. Low-dose subcutaneous interleukin-2 in human multiple myeloma, current results of a phase I/II pilot study. In: Freund M, Link RE, Schmidt E, Welte K, eds. Cytokines in hemopoiesis, oncology and AIDS II. Berlin Heidelberg, Germany: Springer-Verlag, 1992:747-55.
17. Biaise D, Stoppa AM, Olive D, et al. Treatment of relapsed acute leukemias with systemic rIL-2. In: Freund M, Link RE, Schmidt E, Welte K, eds. Cytokines in hemopoiesis, oncology and AIDS II. Berlin Heidelberg, Germany: Springer-Verlag, 1992:763-8.
18. Hall SS. IL-12 holds promise against cancer, glimmer of AIDS hope. Science 1994;263:1684-5.
19. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985;318:745-7.
20. Jarousseau AC, Thibault G, Reverdiau P, et al. Adhesion properties of choriocarcinoma cells towards lymphocytes activated or not by interleukin-2. Cell Immunol 1994;157:38-47.
21. Lindemann A, Brossart P, Hoffken K, et al. Serum cytokine levels in cancer patients treated with different schedules of ultra-low-dose interleukin-2. J Immunother Emphasis Tumor Immunol 1994;15:225-30.
22. Guillaum T, Sekhavat M, Rubinstein DB, Hamdan O, Leblanc P, Symann ML. Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution. Cancer Res 1994;54:3800-7.
23. Crispino S, Lissoni P, Ardizzoia A, et al. Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients. J Biol Regul Homeost Agents 1993;7:92-4.
24. Elasser BU, Gallati H, Weber W, Wild ED, Schultd-Monting J, von-Kleist S. Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients. Tumor Biol 1994;15:17-24.
25. Murakami S, Satomi A, Ishida K, Murai H, Okamura Y. Serum soluble interleukin-2 receptor in colorectal cancer. Acta Oncol 1994;33:19-21.
26. Lotze MT, Custer MC, Sharrow SO, Rubin LA, Nelson DL, Rosenberg SA. In vivo administration of purified human interleukin-2 to patients with cancer: Development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res 1987;47:2188-95.
27. Muller C, Knoflach P, Zielinski C. Soluble interleukin-2 receptor in acute and viral hepatitis and chronic liver disease. Hepatology 1989;19:928-32.
28. Kloster BE, John PA, Miller LE, et al. Soluble interleukin-2 receptors are elevated in patients with AIDS or at risk of developing AIDS. Clin Immunol Immunopathol 1987;45:440-6.
29. Semenzato G, Cipriani A, Trentin I, et al. High serum levels of soluble interleukin-2 receptors in sarcoidosis. Sarcoidosis 1987; 4:25-7.
30. Nakanishi K, Taniguch Y. Increased levels of soluble interleukin-2 receptors in Graves disease. Proceedings of the 8th International Congress of Endocrinology, Kyoto, Japan, July 17-23, 1988:267.
31. Colvin RB, Fuller TC, Mackenn I, Kung PC, IP SH, Cosimi AB. Plasma interleukin 2 receptor levels in renal allograft recipient. Clin Immunol Immunopathol 1987;43:273-76.
32. Stole V, Krause JR. Interleukin-2 receptor levels are increased in blood of heart transplant patients during infections. Diagn Clin Immunol 1987;43:273-8.
33. Wagner DK, Kiwanuka J, Brenda K, Rubbin LA, Nelson DL, Magrath IT. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: Correlation with survival. J Clin Oncol 1987;5:1262-74.
34. Chilosi M, Pizzolo G, Semenzato G, Cetto G. Detection of a soluble form of the receptor for interleukin-2 in the serum of patients with hair cell leukemia. Int J Biol Markers 1986;1:101-4.
35. Pizzalo G, Chilosi M, Vinante F, et al. Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. Br J Cancer 1987;55:427-8.
36. Rovelli F, Lissoni P, Crisino S, et al. Increased levels of soluble interleukin-2 receptor in advanced solid tumors, a preliminary study. Tumori 1988;47:633-7.
37. Lissoni B, Barini S, Rovelli F, et al. The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer 1990;26:32-6.
38. Buccheri G, Marino P, Preatoni A, Ferrigno D, Moroni GA. An indirect marker of tumor activity. Chest 1991;99:1433-6.
39. Cetingul N, Yener E, Oztop S, Nisli G. Serum soluble interleukin-2 receptors and tumor necrosis factor-alpha in hematological malignancies of childhood. Acta Paediatr 1994;36:49-52.
40. Change SC, Hsu YT, Chen YC, Lin CY. Usefulness of soluble interleukin-2 receptors in differentiating tuberculous and carcinomatous pleural effusions. Arch Intern Med 1994;154:1097-101.
41. Hurteau JA, Simon HU, Kurman C, Rubin L, Mills GB. Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients. Am J Obstet Gynecol 1994;170:918-28.
42. Ferdeghini M, Gadducci A, Prontera C, et al. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer. Tumor Biol 1993;14:303-9.
43. Kamihira S, Atogami S, Sohda H, Momita S, Yamada Y, Tomonaga M. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T cell leukemia. Cancer 1994;73:2753-8.
44. Nicholas NS, Panayi GS, Nouri AME. Human pregnancy serum inhibits interleukin-2 production. Clin Exp Immunol 1984;58: 587-95.
45. Lissoni P, Barini S, Rescaldani R, Rovelli F, Tacini G. Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumors. Br J Cancer 1989;60:616-7.
46. Lissoni P, Barni S, Rovelli S, et al. Correlation of serum interleukin-2 levels, soluble interleukin-2 receptors and T-lymphocyte subsets in cancer patients. Tumori 1990;76:14-7.
47. Schirrmacher B, Josomovic-Alasevic O, Osawa H, Dianantstem T. Determination of cell-free interleukin-2 receptor level in the serum of normal animals and of animals bearing IL-2 receptor positive tumours with high or low metastatic capacity. Br J Cancer 1987;55:583-87.
48. Rubin LA, Jay G, Nelson DL. The released interleukin-2 receptor binds interleukin-2 efficiently. J Immunol 1986;137:3841-4.
49. Schlaerth JB. Molar pregnancy termination. Clin Obstet Gynecol 1984;27:1-8.
50. Berkowitz RS, Goldstein DP, Marean NR, Bernstein AM. Oral contraceptives and postmolar trophoblastic disease. Am J Obstet Gynecol 1981;4:474-82.
51. Quigley MM, Tyrey L, Hamond CB. Utility of assay of alpha subunit of hCG in management of gestational trophoblastic malignancies. Am J Obstet Gynecol 1980;138:545-52.
52. Lee JM, Salem HT, Al-Aui AT. Circulating concentrations of specific proteins, hCG, SP and PPS in untreated gestational trophoblastic disease. Am J Obstet Gynecol 1991;139:702-14.
53. Shaarawy M, Nagui A. the diagnostic and prognostic values of serum human chorionic gonadotrophins beta subunits, hPL, β1 pregnancy specific glycoprotein (SP1) and alpha-fetoprotein (AFP) in gestational trophoblastic disease. J Egypt Soc Obstet Gynecol 1983;9:3-12.